Pay in 4 interest-free payments of $5.15 Learn more
Ships within 48 hours · Estimated delivery Aug 15 - Aug 20
Certain factors may increase the likelihood of experiencing bloating on GLP-1 therapy, including: Pre-existing gastrointestinal conditions such as irritable bowel syndrome (IBS), functional dyspepsia, or small intestinal bacterial overgrowth (SIBO) Rapid dose escalation without adequate titration periods Dietary factors , particularly high intake of fermentable carbohydrates (FODMAPs), fatty foods, or carbonated beverages Concurrent medications that affect gastrointestinal motility Patients should be aware that GLP-1 receptor agonists have been associated with more serious gastrointestinal adverse effects, including pancreatitis (inflammation of the pancreas) and gallbladder disease
Hansen SN, Tveden-Nyborg P, Lykkesfeldt J
Targeted activation therapy using saRNA has been validated in various disease animal models
Try these 4 products
Did taking folic acid improve cognitive function among older people with small vessel disease
IGF1 is primarily secreted by the liver and mediates the endocrine actions of growth hormone (GH)
US$ 23.07
US$ 25.61
US$ 20.42
